# Saitama Cancer Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/saitama-cancer-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 46 |
| Citations | 319,770 |
| City | Saitama |
| Country | JP |
| Description | Saitama Cancer Center is a research organisation in Saitama, JP. OpenAlex records 4,553 works and 319,770 citations for it. 633 researchers list it as their most recent affiliation. |
| Homepage | http://www.pref.saitama.lg.jp/saitama-cc/ |
| OpenAlex ID | https://openalex.org/I4210123465 |
| Researchers | 633 |
| ROR ID | https://ror.org/03a4d7t12 |
| Type | healthcare |
| Works | 4,553 |

## University papers

- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial](https://scholariq.org/papers/combination-gemcitabine-plus-s-1-versus-gemcitabine-plus-cisplatin-for-advanced/)
- [Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)](https://scholariq.org/papers/safety-and-efficacy-of-nivolumab-in-combination-with-s-1-capecitabine-plus/)
- [Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study](https://scholariq.org/papers/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or/)

## University top topics

Showing 8 of 25.

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.